Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Exenatide LAR meets endpoint

Amylin (AMLN), Eli Lilly (LLY) and Alkermes (ALKS) said a once-weekly injection of exenatide long-acting release

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE